TOT Biopharm Co., Ltd. held a ground-breaking ceremony for its phase-2 project, the monoclonal antibody production base, on the afternoon of October 17 in Suzhou Industrial Park. 

After its completion, the production base, along with the current 500L-level biological medicine pilot scale test platform, will be used for bio-medicine-related upstream R&D, test production, clinical test, and commercialized production, as well as production of a dozen different kinds of antibody drugs at the same time or alternately, with the expected annual capacity of several hundred kilograms.